Analysis of Disease Free Survival and Overall Survival of HER2 Positive Subtype Breast Cancer Patients at Prof. Dr. I.G.N.G. Ngoerah Denpasar Hospital

Gde Ary Putra Kamajaya; Ni Gusti Ayu Agung Manik Yuniawaty Wetan; I Gede Budhi Setiawan

doi:10.24843/JBN.2025.v09.i01.p01

Gde Ary Putra Kamajaya General Surgery Training Program, Medical Faculty of Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.
Ni Gusti Ayu Agung Manik Yuniawaty Wetan 2 Surgical Oncology Division, Department of Surgery, Medical Faculty of Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.
I Gede Budhi Setiawan 2 Surgical Oncology Division, Department of Surgery, Medical Faculty of Udayana University/Prof. Dr. I.G.N.G Ngoerah General Hospital, Denpasar, Bali, Indonesia.

DOI: https://doi.org/10.24843/JBN.2025.v09.i01.p01

Abstract

Aim: This study aim to assess the characteristics of the patients, as well as the 3-year and 5-year overall survival and disease free survival of HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar Methods: This retrospective cohort study assessed survival rates and prognostic factors among HER2+ breast cancer patients treated at Prof. Dr. I.G.N.G. Ngoerah Hospital Denpasar from January 2017 to December 2022. The study used medical records to examine variables such as age, tumor characteristics, metastasis patterns, histology, treatments, and survival outcomes over 3- and 5-year periods. Results: The 3-year survival rate was 77.7% and the 5-year survival rate was 74.3%, with median survival times of 31 months (95%CI 30.7-32.86) and 49 months (95%CI 47.85-52.089), respectively. Disease-free survival rates indicated median durations of 33 months (95%CI 32.949-34.545) at 3 years and 54 months (95% CI 53.063-56.357) at 5 years. Conclusion: This study enhances understanding of HER2+ breast cancer prognosis, emphasizing the critical roles of lymph node status, metastatic burden, and treatment strategies in determining patient outcomes.

Downloads

Download data is not yet available.

References

1. Globocan. Breast.The Global Cancer Observatory. World Heal Organ. 2020
2. Lyu X, Luo B. Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study. Cancer Med. 2021;10(22):8114–26.
3. Fujita N, Enomoto Y, Inakami K, Yanagisawa T, Iguchi C, Aono T, et al. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab. Oncol. 2020; 98(1):35–41.
4. Ellegård S, Engvall K, Asowed M, Hallbeck AL, Elander N, Stål O. Long-term follow-up of early-stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real-world multicenter cohort study. Front Oncol. 2022;12:861324.
5. Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast. 2022;61:77–83.
6. Cai S, Zuo W, Lu X, Gou Z, Zhou Y, Liu P, et al. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis. Front Oncol. 2020;10:1–10.
7. Patel A, Unni N, Peng Y. The changing paradigm for the treatment of HER2-positive breast cancer. Cancers (Basel). 2020;12(8):2081.
8. Tiruneh M, Tesfaw A, Tesfa D. Survival and Predictors of Mortality among Breast Cancer Patients in Northwest Ethiopia: A Retrospective Cohort Study. Cancer Manag Res. 2021;13:9225–34.
9. Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Res. 2021;23(1):1-10.
10. Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, et al. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat. 2018; 169(3):615–23.
11. Elobaid Y, Aamir M, Grivna M, Suliman A, Attoub S, Mousa H, et al. Breast cancer survival and its prognostic factors in the United Arab Emirates: A retrospective study. PLoS One. 2021; 16:1–10.
12. Houvenaeghel G, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, et al. Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. ESMO Open. 2021;6(6):100316.
13. Sun T, Wang T, Li X, Wang H, Mao Y. Tumor-infiltrating lymphocytes provides recent survival information for early-stage HER2-low-positive breast cancer: a large cohort retrospective study. Front Oncol. 2023;13:1–9.
14. Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open. 2021; 6(3):100114.
15. Movchan OV, Bagmut IY, Shipko AF, Smolanka II, Sheremet MI, Kolisnyk IL, et al. HER2/positive and HER2/low in inflammatory breast cancer recurrence. J Med Life. 2022;15(12):1573–8.
16. Marczyk VR, Rosa DD, Maia AL, Goemann IM. Overall Survival for HER2-Positive Breast Cancer Patients in the HER2-Targeted Era: Evidence From a Population-Based Study. Clin Breast Cancer. 2022;22(5):418–23.
17. Arnetha TS, Hernowo BS, Adha MJ, Rezano A. Relationship between Molecular Subtypes and Overall Survival of Breast Cancer in Bandung. Biomed Pharmacol J.2020;13(3):1543–8.
18. Wijayanto A, Pieter JSLA, Prihantono P, Syamsu SA, Thaufix NS, Abdi A. Survivability Rates Based on Molecular Subtype, Stage and Metastasis of 36 months cohort in Breast Cancer Patients. Nusant Med Sci J. 2022;7(1):29–38.
19. Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomized phase 3 non-inferiority trial. Lancet. 2019; 393(10191):2599–612.
20. Ayuza M, Harahap WA, Rustam R, Nindrea RD. Factors Affecting Disease Free Survival and Overall Survival in Young Breast Cancer Patients in Padang City in 2008 - 2018. J Andalas' Health. 2020; 9(1S):65–73.